DK3710485T3 - Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder - Google Patents

Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder Download PDF

Info

Publication number: DK3710485T3
Authority: DK; Denmark
Prior art keywords: methods; sez6 antibody; conjugates; medicinal; medicinal conjugates
Prior art date: 2018-05-30

Application number

DK19732174.8T

Other languages

English (en)

Inventor

David Liu

Alexander Schammel

Julia Gavrilyuk

Original Assignee

Abbvie Stemcentrx Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-30

Filing date

2019-05-30

Publication date

2021-05-10

2019-05-30 Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc

2021-05-10 Application granted granted Critical

2021-05-10 Publication of DK3710485T3 publication Critical patent/DK3710485T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK19732174.8T 2018-05-30 2019-05-30 Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder DK3710485T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862678061P	2018-05-30	2018-05-30
PCT/US2019/034701 WO2019232241A1 (en)	2018-05-30	2019-05-30	Anti-sez6 antibody drug conjugates and methods of use

Publications (1)

Publication Number	Publication Date
DK3710485T3 true DK3710485T3 (da)	2021-05-10

Family

ID=66998493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK19732174.8T DK3710485T3 (da)	2018-05-30	2019-05-30	Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder

Country Status (32)

Country	Link
US (4)	US20210196834A1 (da)
EP (2)	EP3858863A1 (da)
JP (1)	JP6936399B2 (da)
KR (1)	KR20210018316A (da)
CN (1)	CN112135843A (da)
AU (1)	AU2019278870A1 (da)
BR (1)	BR112020024223A2 (da)
CA (1)	CA3097199A1 (da)
CL (1)	CL2020003044A1 (da)
CO (1)	CO2020016151A2 (da)
CR (1)	CR20200623A (da)
CY (1)	CY1124183T1 (da)
DK (1)	DK3710485T3 (da)
EC (1)	ECSP20082970A (da)
ES (1)	ES2867148T3 (da)
HR (1)	HRP20210631T1 (da)
HU (1)	HUE053616T2 (da)
IL (1)	IL278225A (da)
LT (1)	LT3710485T (da)
MA (1)	MA51453A (da)
MX (1)	MX2020012788A (da)
NZ (1)	NZ768778A (da)
PE (1)	PE20211497A1 (da)
PH (1)	PH12020551968A1 (da)
PL (1)	PL3710485T3 (da)
PT (1)	PT3710485T (da)
RS (1)	RS61770B1 (da)
RU (1)	RU2770474C1 (da)
SG (1)	SG11202011576VA (da)
SI (1)	SI3710485T1 (da)
SM (1)	SMT202100368T1 (da)
WO (1)	WO2019232241A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102819556B1 (ko)	2021-05-10	2025-06-13	강원대학교산학협력단	항체 결합 재조합 융합 단백질 및 이를 이용한 항체-약물 접합체
WO2022240117A1 (ko)	2021-05-10	2022-11-17	강원대학교 산학협력단	항체 결합 재조합 융합 단백질 및 이를 이용한 항체-약물 접합체
AU2023331263A1 (en) *	2022-08-26	2025-02-27	Abbvie Inc.	Anti-sez6 antibody drug conjugates
AU2024270504A1 (en)	2023-05-08	2025-11-27	Changzhou Hansoh Pharmaceutical Co., Ltd.	Antibody or antigen-binding fragment thereof, antibody-drug conjugate, and use thereof
WO2025167503A1 (en) *	2024-02-05	2025-08-14	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Anti-sez6/b7h3 antibodies and uses thereof
CN120904329A (zh) *	2024-10-18	2025-11-07	北京大学第一医院(北京大学第一临床医学院)	一种抗sez6纳米抗体或抗原结合片段与应用
CN120365421B (zh) *	2025-04-24	2025-11-04	成都古格尔生物技术有限公司	一种特异性抗sez6靶点的全人源抗体及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1986005807A1 (en)	1985-04-01	1986-10-09	Celltech Limited	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
US5879936A (en)	1988-04-18	1999-03-09	Aluguisse Holding A.G.	Recombinant DNA methods, vectors and host cells
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
ES2593304T3 (es) *	2002-05-02	2016-12-07	Wyeth Holdings Llc	Conjugados de transportador derivado de caliqueamicina
TW200539855A (en) *	2004-03-15	2005-12-16	Wyeth Corp	Calicheamicin conjugates
CA2574881C (en)	2004-08-04	2013-01-08	Amgen Inc.	Antibodies to dkk-1
CN106620693A (zh)	2010-09-03	2017-05-10	艾伯维施特姆森特克斯有限责任公司	新型调节剂及使用方法
PE20150091A1 (es) *	2012-02-24	2015-02-16	Stem Centrx Inc	Anticuerpos anti-sez6 y metodos de empleo
WO2015003154A1 (en)	2013-07-03	2015-01-08	Histosonics, Inc.	Articulating arm limiter for cavitational ultrasound therapy system
CA2922529A1 (en) *	2013-08-28	2015-03-05	Stemcentrx, Inc.	Novel sez6 modulators and methods of use
WO2015031698A1 (en) *	2013-08-28	2015-03-05	Stem Centrx, Inc.	Site-specific antibody conjugation methods and compositions
MA41645A (fr) *	2015-03-04	2018-01-09	Abbvie Stemcentrx Llc	Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
AR104333A1 (es) *	2015-04-21	2017-07-12	Stemcentrx Inc	Constructos de calicheamicina y métodos de uso
BR112018012884A2 (pt) *	2015-12-22	2018-12-04	Abbvie Stemcentrx Llc	novos anticorpos anti-mmp16 e métodos de uso
CA3027044A1 (en) *	2016-06-08	2017-12-14	Abbvie Inc.	Anti-b7-h3 antibodies and antibody drug conjugates

2019
- 2019-05-30 CA CA3097199A patent/CA3097199A1/en active Pending
- 2019-05-30 SG SG11202011576VA patent/SG11202011576VA/en unknown
- 2019-05-30 BR BR112020024223-3A patent/BR112020024223A2/pt not_active Application Discontinuation
- 2019-05-30 DK DK19732174.8T patent/DK3710485T3/da active
- 2019-05-30 JP JP2020534838A patent/JP6936399B2/ja active Active
- 2019-05-30 KR KR1020207037003A patent/KR20210018316A/ko not_active Ceased
- 2019-05-30 PE PE2020001901A patent/PE20211497A1/es unknown
- 2019-05-30 LT LTEP19732174.8T patent/LT3710485T/lt unknown
- 2019-05-30 WO PCT/US2019/034701 patent/WO2019232241A1/en not_active Ceased
- 2019-05-30 PL PL19732174T patent/PL3710485T3/pl unknown
- 2019-05-30 MX MX2020012788A patent/MX2020012788A/es unknown
- 2019-05-30 RS RS20210516A patent/RS61770B1/sr unknown
- 2019-05-30 SM SM20210368T patent/SMT202100368T1/it unknown
- 2019-05-30 SI SI201930050T patent/SI3710485T1/sl unknown
- 2019-05-30 RU RU2020141419A patent/RU2770474C1/ru active
- 2019-05-30 ES ES19732174T patent/ES2867148T3/es active Active
- 2019-05-30 PT PT197321748T patent/PT3710485T/pt unknown
- 2019-05-30 HU HUE19732174A patent/HUE053616T2/hu unknown
- 2019-05-30 HR HRP20210631TT patent/HRP20210631T1/hr unknown
- 2019-05-30 EP EP21157876.0A patent/EP3858863A1/en not_active Withdrawn
- 2019-05-30 NZ NZ768778A patent/NZ768778A/en unknown
- 2019-05-30 CR CR20200623A patent/CR20200623A/es unknown
- 2019-05-30 AU AU2019278870A patent/AU2019278870A1/en active Pending
- 2019-05-30 EP EP19732174.8A patent/EP3710485B8/en active Active
- 2019-05-30 US US16/904,463 patent/US20210196834A1/en not_active Abandoned
- 2019-05-30 MA MA051453A patent/MA51453A/fr unknown
- 2019-05-30 CN CN201980033447.XA patent/CN112135843A/zh active Pending
2020
- 2020-06-22 US US16/908,645 patent/US11077203B2/en active Active
- 2020-10-21 IL IL278225A patent/IL278225A/en unknown
- 2020-11-18 PH PH12020551968A patent/PH12020551968A1/en unknown
- 2020-11-24 CL CL2020003044A patent/CL2020003044A1/es unknown
- 2020-12-23 CO CONC2020/0016151A patent/CO2020016151A2/es unknown
- 2020-12-23 EC ECSENADI202082970A patent/ECSP20082970A/es unknown
2021
- 2021-04-29 CY CY20211100371T patent/CY1124183T1/el unknown
- 2021-07-09 US US17/372,354 patent/US20210338831A1/en not_active Abandoned
2025
- 2025-02-27 US US19/065,518 patent/US20250213714A1/en active Pending

Also Published As

Publication number	Publication date
CL2020003044A1 (es)	2021-04-16
US20210196834A1 (en)	2021-07-01
US11077203B2 (en)	2021-08-03
ES2867148T3 (es)	2021-10-20
EP3858863A1 (en)	2021-08-04
PH12020551968A1 (en)	2021-09-13
IL278225A (en)	2020-11-30
PT3710485T (pt)	2021-05-04
LT3710485T (lt)	2021-05-10
PL3710485T3 (pl)	2021-09-13
EP3710485B8 (en)	2021-06-23
JP2021508694A (ja)	2021-03-11
SG11202011576VA (en)	2020-12-30
BR112020024223A2 (pt)	2021-03-16
HUE053616T2 (hu)	2021-07-28
NZ768778A (en)	2022-07-01
ECSP20082970A (es)	2021-01-29
AU2019278870A1 (en)	2020-10-29
US20200316215A1 (en)	2020-10-08
US20210338831A1 (en)	2021-11-04
MX2020012788A (es)	2021-02-15
HRP20210631T1 (hr)	2021-05-28
EP3710485B1 (en)	2021-03-31
KR20210018316A (ko)	2021-02-17
PE20211497A1 (es)	2021-08-11
JP6936399B2 (ja)	2021-09-15
US20250213714A1 (en)	2025-07-03
CR20200623A (es)	2021-07-01
CO2020016151A2 (es)	2021-05-31
SMT202100368T1 (it)	2021-07-12
RU2770474C1 (ru)	2022-04-18
MA51453A (fr)	2020-09-23
WO2019232241A1 (en)	2019-12-05
EP3710485A1 (en)	2020-09-23
RS61770B1 (sr)	2021-05-31
CY1124183T1 (el)	2022-05-27
SI3710485T1 (sl)	2021-08-31
CN112135843A (zh)	2020-12-25
CA3097199A1 (en)	2019-12-05

Publication	Publication Date	Title
DK3784283T3 (da)	2024-11-25	Cannabidiopræparater og anvendelser deraf
DK3774789T3 (da)	2025-06-10	BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3946464T3 (da)	2022-10-31	Forbindelser og konjugater deraf
DK3732185T3 (da)	2025-03-31	Konjugater og fremstilling og anvendelse heraf
DK3610005T3 (da)	2021-12-13	Peptidligase og anvendelse deraf
DK3737765T4 (da)	2025-03-24	Forstærkede immunceller med dobbelt shrna og sammensætning dermed
DK3625263T3 (da)	2025-06-30	Anti-galectin- 9-antistoffer og anvendelser deraf
DK3626825T3 (da)	2024-12-09	Anti-cdh6-antistof og anti-cdh6-antistof-lægemiddelkonjugat
DK3601358T3 (da)	2023-07-31	Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da)	2023-08-21	Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3383916T3 (da)	2022-03-28	Anti-CD73-antistoffer og anvendelser deraf
DK3458479T3 (da)	2021-02-08	Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
DK3448386T3 (da)	2021-04-26	Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3658192T3 (da)	2021-06-21	Glucocorticoid-receptoragonist og immunokonjugater deraf
DK3653221T5 (da)	2024-08-26	Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3618928T5 (da)	2024-09-02	Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3710485T3 (da)	2021-05-10	Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder
IL283782A (en)	2021-07-29	Anellosomes and methods of use
DK3596125T3 (da)	2025-12-22	Anti-PAR2-antistoffer og anvendelser deraf
DK3525583T3 (da)	2025-10-27	Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3557998T3 (da)	2023-11-20	Sammensætninger, kompositioner og anvendelsesmetoder
IL283787A (en)	2021-07-29	Herboxidiene antibody-drug conjugates and methods of use
DK3430129T5 (da)	2024-09-16	Kolonidannende medium og anvendelse deraf
DK3710430T3 (da)	2024-09-09	Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3621694T3 (da)	2023-09-11	Lrrc33-inhibitorer og anvendelse heraf